The effects of CpG-ODNs and Chitosan adjuvants on the elicitation of immune responses induced by the HIV-1-Tat-based candidate vaccines in mice
- PMID: 28175274
- DOI: 10.1093/femspd/ftx013
The effects of CpG-ODNs and Chitosan adjuvants on the elicitation of immune responses induced by the HIV-1-Tat-based candidate vaccines in mice
Abstract
HIV1-Tat-based vaccines could elicit broad, durable and neutralizing immune responses and are considered as potential AIDS vaccines. The present study aims to formulate CpG-ODNs adjuvant and Chitosan with Tat protein to enhance the immunogenicity of HIV-1-Tat-based candidate vaccines and to investigate their efficacies in mice. To this end, we added CpG-ODNs, Chitosan and Alum as adjuvants to the Tat-based candidate vaccine formulations. Then, we compared frequency and magnitude of both humoral and cellular immune responses from mice immunized with the adjuvant-formulated Tat candidate vaccines against those obtained from mice immunized with recombinant Tat protein alone. Mice were subcutaneously immunized three times at 2-week intervals with the candidate vaccines. Measurements of anti-Tat immune responses showed that all vaccinated groups had a good immunity compared to the control groups and developed high levels of both humoral and cellular responses. However, immunized mice with CpG-ODNs, and Chitosan-adjuvanted Tat vaccines elicited stronger T-cell responses (both humoral and cellular immunity) compared to the others. These data suggest that co-administration of recombinant Tat protein with CpG-ODNs and Chitosan may serve as a potential formulation for enhancing of the Tat vaccine-induced immunity and might have effects on shaping Th polarization induced by HIV1-Tat protein vaccines.
Keywords: Alum; Chitosan; CpG-ODNs; HIV-1 vaccine; Tat protein; cellular and humoral immunity.
© FEMS 2017. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Similar articles
-
Subcutaneous administration CpG-ODNs acts as a potent adjuvant for an HIV-1-tat-based vaccine candidate to elicit cellular immunity in BALB/c mice.Biotechnol Lett. 2018 Mar;40(3):527-533. doi: 10.1007/s10529-017-2497-9. Epub 2018 Jan 8. Biotechnol Lett. 2018. PMID: 29313255
-
Formulation of chitosan with the polyepitope HIV-1 protein candidate vaccine efficiently boosts cellular immune responses in mice.Pathog Dis. 2017 Nov 30;75(8). doi: 10.1093/femspd/ftx098. Pathog Dis. 2017. PMID: 28911033
-
Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.J Virol. 2005 Aug;79(15):9872-84. doi: 10.1128/JVI.79.15.9872-9884.2005. J Virol. 2005. PMID: 16014948 Free PMC article.
-
Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate.Rev Recent Clin Trials. 2009 Sep;4(3):195-204. doi: 10.2174/157488709789957529. Rev Recent Clin Trials. 2009. PMID: 20028332 Review.
-
Modulation of HIV-1 immunity by adjuvants.Curr Opin HIV AIDS. 2014 May;9(3):242-9. doi: 10.1097/COH.0000000000000052. Curr Opin HIV AIDS. 2014. PMID: 24670321 Free PMC article. Review.
Cited by
-
Immunogenicity evaluation of the HIV-1 Tat containing polyepitope DNA vaccine adjuvanted with CpG-ODNs in mice.Iran J Basic Med Sci. 2021 Mar;24(3):377-382. doi: 10.22038/ijbms.2021.52890.11923. Iran J Basic Med Sci. 2021. PMID: 33995949 Free PMC article.
-
Subcutaneous administration CpG-ODNs acts as a potent adjuvant for an HIV-1-tat-based vaccine candidate to elicit cellular immunity in BALB/c mice.Biotechnol Lett. 2018 Mar;40(3):527-533. doi: 10.1007/s10529-017-2497-9. Epub 2018 Jan 8. Biotechnol Lett. 2018. PMID: 29313255
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical